BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hebei Senlang Biotechnology readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Hebei Senlang Biotechnology's dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07421856-3269@assetmemo.bio
DTSTAMP:20261121T005931Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:SENL103: Phase 1/2 readout est. (NCT07421856)
DESCRIPTION:SENL103\, phase 1/2\, Multiple Myeloma.\nStudy: Phase I/II Stud
 y of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter\, 
 Open-Label\, Single-Arm Trial.\nEstimated primary completion: 1 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/senl103#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07421856
URL:https://assetmemo.bio/drug/senl103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
